When Schedule I faced copyright infringement claims, an unexpected backlash occurred as fans targeted the accuser's games with negative reviews. Here's the full story behind this gaming controversy and what's next for Schedule I.

Schedule I Recent Updates

Backlash Ensues as Copyright Complaint Sparks Fan Uprising

The indie drug trade simulator Schedule I finds itself at the center of a copyright dispute with Movie Games S.A., creators of The Drug Dealer Simulator series. According to a Polish Press Agency report dated April 3, Movie Games completed a legal review suggesting Schedule I may have copied plot elements, gameplay mechanics, and UI design.

Though no formal legal action has been taken yet, gaming communities have passionately taken sides, with overwhelming support favoring Schedule I. Both The Drug Dealer Simulator and its sequel have been flooded with negative Steam reviews, resulting in "Overwhelmingly Negative" and "Mostly Negative" ratings respectively.

The critical reviews primarily accuse Movie Games of unfairly targeting an indie developer while ignoring similar previous titles in the genre. This backlash comes despite the series previously earning praise as standout criminal management games from both critics and players.

Schedule I offers a cooperative crime experience where players rise from street-level dealers to drug kingpins. Since its March 25 Early Access launch on PC, the game maintains an "Overwhelmingly Positive" rating on Steam and currently ranks as the platform's #2 top-seller, outpacing major titles like inZOI and Monster Hunter Wilds. SteamDB reports Schedule I achieved an impressive peak of 459,075 concurrent players.

Game8's review praised Schedule I as an unexpectedly compelling experience akin to a "Breaking Bad" simulator. For our complete thoughts on the Early Access version, check out our detailed analysis.